[1] |
Kim EH, JA Larson, and GL Andriole. Management of benign prostatic hyperplasia. Annu Rev Med 2016; 67:137-151.
doi: 10.1146/annurev-med-063014-123902
pmid: 26331999
|
[2] |
Zhu C, DQ Wang, H Zi, Q Huang, JM Gu, LY Li, et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil Med Res 2021; 8:64.
doi: 10.1186/s40779-021-00359-8
pmid: 34879880
|
[3] |
Chen J, D Zhang, W Yan, D Yang, and B Shen. Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era . Biomed Res Int 2013;901578.
|
[4] |
Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008; 20 Suppl 3:S11-18.
|
[5] |
McNeal JE, EA Redwine, FS Freiha, and TA Stamey. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12:897-906.
doi: 10.1097/00000478-198812000-00001
pmid: 3202246
|
[6] |
Institute, NC. Understanding prostate changes: a health guide for men. https://www.cancer.gov/types/prostate/understanding-prostate-changes.
|
[7] |
Sommers SC. Endocrine changes with prostatic carcinoma. Cancer 1957; 10:345-358.
pmid: 13426991
|
[8] |
Bostwick DG, WH Cooner, L Denis, GW Jones, PT Scardino, and GP Murphy, The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992; 70:291-301.
doi: 10.1002/1097-0142(19920701)70:1+<291::aid-cncr2820701317>3.0.co;2-4
pmid: 1376199
|
[9] |
Tanaka T, T Koie, C Ohyama, Y Hashimoto, A Imai, Y Tobisawa, et al. Incidental prostate cancer in patients with muscle-invasive bladder cancer who underwent radical cystoprostatectomy. Jpn J Clin Oncol 2017; 47:1078-1082.
doi: 10.1093/jjco/hyx119
pmid: 28973396
|
[10] |
JY Joung, SO Yang, HK Seo, TS Kim, KS Han, J.Chung, et al. Incidental prostate cancer detected by cystoprostatectomy in Korean men. Urology 2009; 73:153-157.
doi: 10.1016/j.urology.2008.02.040
pmid: 18407328
|
[11] |
He B, Z Zhao, Q Cai, Y Zhang, P Zhang, S Shi, et al. miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci 2020; 16:2628-2647.
doi: 10.7150/ijbs.47203
pmid: 32792861
|
[12] |
Greco F, A Inferrera, R La Rocca, M Navarra, M Casciaro, G Grosso, et al. The potential role of microRNAs as biomarkers in benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus 2019; 5:497-507.
doi: S2405-4569(18)30009-9
pmid: 29398458
|
[13] |
Macedo Hair G, F Fonseca Nobre, and P Brasil. Characterization of clinical patterns of dengue patients using an unsupervised machine learning approach. BMC Infect Dis 2019; 19:649.
doi: 10.1186/s12879-019-4282-y
pmid: 31331271
|
[14] |
Yan J, L Liu, W Wang, Y Zhao, KK Li, K Li, et al. Radiomic features from multi-parameter MRI combined with clinical parameters predict molecular subgroups in patients with medulloblastoma. Front Oncol 2020; 10:558162.
doi: 10.3389/fonc.2020.558162
|
[15] |
De Nunzio C, S Ahyai, R Autorino, A Bachmann, W Bialek, A Briganti, et al. Benign prostatic hyperplasia and lower urinary tract symptoms: research priorities. Eur Urol 2011; 60:1205-1206.
doi: 10.1016/j.eururo.2011.08.055
pmid: 21930341
|
[16] |
Langan RC, Benign prostatic hyperplasia. Prim Care 2019; 46:223-232.
doi: S0095-4543(19)30006-5
pmid: 31030823
|
[17] |
Wang S, Q Mao, Y Lin, J Wu, X Wang, X Zheng, et al. Body mass index and risk of BPH: a meta-analysis. Prostate Cancer Prostatic Dis 2012; 15:265-272.
doi: 10.1038/pcan.2011.65
|
[18] |
Wang YB, L Yang, YQ Deng, SY Yan, LS Luo, P Chen, et al. Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study. J Transl Med 2022; 20:495.
doi: 10.1186/s12967-022-03722-y
|
[19] |
Li BH, T Deng, Q Huang, H Zi, H Weng, and XT Zeng. Body mass index and risk of prostate volume, international prostate symptom score, maximum urinary flow rate, and post-void residual in benign prostatic hyperplasia patients. Am J Mens Health 2019; 13:1557988319870382.
|
[20] |
Parsons JK, AV Sarma, K McVary, and JT Wei. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 2009; 182:S27-S31.
|
[21] |
Kabekkodu SP, V Shukla, VK Varghese, DS J, S Chakrabarty, and K Satyamoorthy. Clustered miRNAs and their role in biological functions and diseases. Biol Rev Camb Philos Soc 2018; 93:1955-1986.
doi: 10.1111/brv.12428
pmid: 29797774
|
[22] |
Zhang N, Z Li, F Bai, N Ji, Y Zheng, Y Li, et al. MicroRNA expression profiles in benign prostatic hyperplasia. Mol Med Rep 2018; 17:3853-3858.
doi: 10.3892/mmr.2017.8318
pmid: 29359788
|
[23] |
Cochetti G, G Poli, G Guelfi, A Boni, MG Egidi, and E Mearini. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role. Onco Targets Ther 2016; 9:7545-7553.
doi: 10.2147/OTT
|